Immune Pharma names Paul Nadler CMO
This article was originally published in Scrip
Immune Pharmaceuticals has appointed Dr Paul Nadler acting executive vice-president of R&D, and chief medical officer. In this position, Dr Nadler will be responsible for overseeing the development of Immune's immunology and oncology pipeline. Dr Nadler has been an interim or acting CMO (or similar) for a variety of early stage biotechnology companies such as OSI Pharmaceuticals, Fast Track Systems, Alexion Pharmaceuticals, CGI Pharma, Phylogix, Aveo, Dicerna and others.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.